Price Comparison
Liraglutide
GLP-1 Peptide
1 of 1 vendors
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| CertaPeptides 7.5/10 COA ✓Ships: InternationalPayment not verified Verification & shipping7.5/10 COA ✓Ships: InternationalPayment not verified | $75.1810mg package | $75.18Checked jun 27, 2026 | Jun 27, 2026 | Buy Liraglutide from CertaPeptides |
Research details
Liraglutide — research data
Half-life~13 hours. Daily SC injection required.
Regulatory statusFDA-approved (Victoza/Saxenda)
NCAA D1Not listed
Overview
About Liraglutide
Mechanism of action
GLP-1 receptor agonist (97% homology to human GLP-1); stimulates insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite. Daily injection (vs. weekly for GLP-1S).
Safety profile
Nausea, vomiting, diarrhea, constipation; pancreatitis risk; thyroid C-cell tumor risk (rodents); gallbladder disease; injection site reactions. · Extensive data; GI side effects; thyroid warning (animal); cardiovascular benefit demonstrated
Storage
Stability & handling
Lyophilized (powder)−20°Clong-term stable
Reconstituted2–8°Cwithin 30 days
Related pages
More on Liraglutide
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- The SCALE Obesity trial (NEJM 2015, n=3,731) demonstrated that liraglutide 3.0 mg as Saxenda produced a mean 8.4% body weight reduction vs 2.8% with placebo over 56 weeks — with 63.2% of participants achieving ≥5% weight loss, leading to FDA approval for chronic weight management.
- The LEADER cardiovascular outcomes trial (NEJM 2016, n=9,340) showed liraglutide 1.8 mg significantly reduced the MACE composite endpoint by 13% (HR 0.87, p=0.01) in T2D patients at high cardiovascular risk over a median 3.8 years — establishing the first cardiovascular mortality benefit for a GLP-1 agonist.